Skandinaviska Enskilda Banken AB publ Sells 47,500 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Skandinaviska Enskilda Banken AB publ cut its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 35.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 84,900 shares of the company’s stock after selling 47,500 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in GoodRx were worth $383,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Rubric Capital Management LP boosted its holdings in shares of GoodRx by 25.2% during the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after buying an additional 943,226 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in GoodRx during the third quarter worth about $11,295,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in GoodRx by 38.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company’s stock worth $5,714,000 after acquiring an additional 342,781 shares in the last quarter. Geode Capital Management LLC grew its holdings in GoodRx by 6.3% in the third quarter. Geode Capital Management LLC now owns 982,729 shares of the company’s stock worth $6,823,000 after purchasing an additional 58,610 shares during the period. Finally, Franklin Resources Inc. bought a new position in shares of GoodRx during the third quarter valued at approximately $5,675,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Stock Performance

Shares of NASDAQ GDRX opened at $4.46 on Tuesday. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm’s 50-day moving average price is $4.72 and its 200-day moving average price is $5.48. GoodRx Holdings, Inc. has a 52-week low of $4.09 and a 52-week high of $9.26. The company has a market cap of $1.71 billion, a PE ratio of -148.67, a PEG ratio of 2.46 and a beta of 1.25.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Mizuho began coverage on GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target on the stock. Wells Fargo & Company cut their target price on GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Citigroup lowered their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research report on Friday, January 10th. KeyCorp cut their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Finally, Morgan Stanley decreased their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.18.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.